Research Article
Prognosis and Microbiome Analysis of First-Line Consolidation with Autologous Hematopoietic Stem Cell Transplantation in Intermediate-to-High-Risk Diffuse Large B-Cell Lymphoma
Xiaomin Xian1,#, Shan Liu2,#, Jing Xie1,#, Yueqiao Wang1,#, Xuanyong Liu1,*, Zhi Guo1,2,*
1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China. 2Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China.
#, Authors contributed equally. *, Correspondence Professor Zhi Guo, PhD, Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China. E-mail: guozhi77@126.com. Professor Xuanyong Liu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China. E-mail: 694879845@qq.com Received: July 1, 2026. Accepted: July 5, 2026. Published online: November 16, 2026. Cite this paper: Xiaomin Xian, Shan Liu, Jing Xie, Yueqiao Wang, Xuanyong Liu, Zhi Guo. Prognosis and Microbiome Analysis of First-Line Consolidation with Autologous Hematopoietic Stem Cell Transplantation in Intermediate-to-High-Risk Diffuse Large B-Cell Lymphoma. Global Journal of Microbiology, 2026;7(2):52-69. http://naturescholars.com/gjmic.070205. https://doi.org/10.46633/gjmic.070205. Copyright © 2026 by Scholars Publishing, LLC.
Abstract
Objective: To evaluate the safety and efficacy of first-line consolidation with autologous hematopoietic stem cell transplantation (AHSCT) in intermediate-to-high-risk diffuse large B-cell lymphoma (DLBCL). Methods: A total of 70 newly diagnosed, intermediate-to-high-risk DLBCL patients who achieved complete response (CR) after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy at the Department of Hematologic Oncology, Cancer Hospital of the Chinese Academy of Medical Sciences, Shenzhen Hospital between June 2018 and December 2023 were retrospectively analyzed. Patients who received sequential AHSCT as first-line consolidation therapy were included in the transplantation group (n = 35), whereas those who did not receive sequential AHSCT consolidation during the same period served as the control group (n = 35). The clinical efficacy and safety were compared between the two groups. Results: As of the final follow-up on December 31, 2025, the median follow-up time was 59 (51–63) months in the transplantation group and 62 (45–68) months in the control group. The 5-year disease-free survival (DFS) rate in the transplantation group was significantly higher than that in the control group (66.7% vs. 44.7%, P = 0.012); however, no statistically significant difference was observed in the 5-year overall survival (OS) rate (70.6% vs. 62.5%, P = 0.42). Cox multivariate analysis indicated that non-sequential AHSCT consolidation therapy, double expression, and bone marrow involvement (BMI) were independent adverse prognostic factors for DFS (HR = 5.583, 95%CI = 2.199–14.175, P < 0.001; HR = 3.240, 95% CI = 1.492–7.037, P = 0.003; HR = 6.225, 95% CI = 2.535–15.282, P < 0.001, respectively). In 15 transplanted patients treated with the oropharyngeal probiotic BP-OM1, salivary levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were significantly elevated compared to the controls. No transplant-related mortality occurred in the transplantation group, and bacterial, fungal, and viral infections occurring during the peri-transplantation period were completely cured after symptomatic treatment. Conclusion: For patients with newly diagnosed intermediate-to-high-risk DLBCL who achieve CR after R-CHOP chemotherapy, sequential first-line consolidation with AHSCT can significantly improve the DFS rate with favorable safety and efficacy.
Keywords
Autologous hematopoietic stem cell transplantation (AHSCT); intermediate-to-high-risk; diffuse large B-cell lymphoma (DLBCL); Safety; Efficacy.